Non-invasive cell tracking in cancer and cancer therapy.
Non-invasive cell tracking in cancer and cancer therapy.
复制标题
DOI：
10.2174/156802610791384234
复制
发表时间：
2010
影响因子：
3.4
通讯作者：
Cai W
中科院分区：
文献类型：
--
作者：
Hong H;Yang Y;Zhang Y;Cai W
基于细胞的治疗为癌症治疗带来了巨大的希望。非侵入性地跟踪各种治疗性细胞（例如T细胞和干细胞）向肿瘤部位的递送和/或这些细胞的后续分化/增殖的能力将允许更好地理解癌症发展和干预的机制。本文将简要综述非侵入性细胞追踪在癌症和癌症治疗中的各种方法。一般来说，有两种方法用于细胞跟踪：直接（细胞用某些标签标记，可以用合适的成像设备直接检测）和间接细胞标记（通常使用报告基因方法）。描述了用于跟踪癌症中的各种细胞类型（例如免疫细胞、干细胞和癌细胞）的技术，其包括荧光、生物发光、正电子发射断层扫描（PET）、单光子发射计算机断层扫描（SPECT）和磁共振成像（MRI）。免疫和干细胞的非侵入性跟踪主要用于（潜在的）癌症治疗应用，而癌细胞的跟踪可以进一步了解癌症的发展和肿瘤转移。安全性是未来临床应用的主要关注点，并且用于跟踪癌症患者中的治疗细胞的理想成像模式需要成像标签无毒、生物相容性和高度特异性。每种成像方式都有其优点和缺点，它们更多的是互补而不是竞争。MRI、基于放射性核素的成像技术和基于报告基因的方法将各自有自己的利基，以实现相同的最终目标：为癌症患者提供个性化医疗。
Cell-based therapy holds great promise for cancer treatment. The ability to non-invasively track the delivery of various therapeutic cells (e.g. T cells and stem cells) to the tumor site, and/or subsequent differentiation/proliferation of these cells, would allow better understanding of the mechanisms of cancer development and intervention. This brief review will summarize the various methods for non-invasive cell tracking in cancer and cancer therapy. In general, there are two approaches for cell tracking: direct (cells are labeled with certain tags that can be detected directly with suitable imaging equipment) and indirect cell labeling (which typically uses a reporter gene approach). The techniques for tracking various cell types (e.g. immune cells, stem cells, and cancer cells) in cancer are described, which include fluorescence, bioluminescence, positron emission tomography (PET), single-photon emission computed tomography (SPECT), and magnetic resonance imaging (MRI). Non-invasive tracking of immune and stem cells were primarily intended for (potential) cancer therapy applications while tracking of cancer cells could further our understanding of cancer development and tumor metastasis. Safety is a major concern for future clinical applications and the ideal imaging modality for tracking therapeutic cells in cancer patients requires the imaging tags to be non-toxic, biocompatible, and highly specific. Each imaging modality has its advantages and disadvantages and they are more complementary than competitive. MRI, radionuclide-based imaging techniques, and reporter gene-based approaches will each have their own niches towards the same ultimate goal: personalized medicine for cancer patients.
登录
查看更多内容
影响因子：
2.8
作者：
Dotti, Gianpietro;Tian, Mei;Gelovani, Juri G.
通讯作者：
Gelovani, Juri G.
影响因子：
20.3
作者：
Baker, J;Verneris, MR;Negrin, RS
通讯作者：
Negrin, RS
影响因子：
10.3
作者：
DUMMER, R;BECKER, JC;BURG, G
通讯作者：
BURG, G
影响因子：
3.5
作者：
Hoffman, RM
通讯作者：
Hoffman, RM
影响因子：
14.8
作者：
Cai, Weibo;Chen, Xiaoyuan
通讯作者：
Chen, Xiaoyuan